

ORIGINAL ARTICLE

Use of direct oral anticoagulants in patients with stroke transferred for thrombectomy



Ana Isabel Rodrigues^{a,*}, Inês V. Carvalho^b, Carolina Sousa Fernandes^b, Francisco Millet Barros^b, João Sousa^b, Pedro Faustino^b, Emanuel Martins^b, Diogo Damas^b, Catarina Bernardes^b, Carolina Teles^b, Telma Alves^b, Carolina Martins^b, Rita Ramalho^b, Carolina Maia^b, Henrique Queirós^b, Elisa Viegas^c, Filipa Costa Sousa^c, Inês Pinheiro^d, Laura Baptista^d, Ana Patrícia Gomes^e, Fábia Cruz^f, Jéssica Fidalgo^g, André Carvalho^h, Carla Nunes^b, Cristina Machado^b, Bruno Rodrigues^b, Luciano Almendra^b, Fernando Silva^b, César Nunes^b, Ricardo Veiga^b, Dulcídia Sá^d, Emanuel Araújo^a, Eugénia André^f, Fátima Paiva^e, João Correia^g, Abílio Gonçalves^h, Ana Gomes^c, João Sargent-Freitas^b, Egídio Machado^b, Gustavo C. Santo^{b,i}

^a Unidade Local de Saúde de Leiria, Leiria, Portugal

^b Unidade Local de Saúde de Coimbra, Coimbra, Portugal

^c Unidade Local de Saúde de Viseu Dão Lafões, Viseu, Portugal

^d Unidade Local de Saúde da Região de Aveiro, Aveiro, Portugal

^e Unidade Local de Saúde da Cova da Beira, Covilhã, Portugal

^f Unidade Local de Saúde de Castelo Branco, Castelo Branco, Portugal

^g Unidade Local de Saúde da Guarda, Guarda, Portugal

^h Unidade Local de Saúde do Baixo Mondego, Figueira da Foz, Portugal

ⁱ Administração Regional de Saúde do Centro, Coimbra, Portugal

Received 27 April 2024; accepted 29 January 2025

Available online 2 June 2025

KEYWORDS

Ischemic stroke;
Direct oral
anticoagulants;
Thrombolysis;
Thrombectomy;
Telestroke network

Abstract

Introduction and objectives: Regional telestroke networks offer several advantages, including upstream selection of thrombectomy candidates. However, it is unclear whether the network performance and the functional outcome of patients with ischemic stroke treated with direct oral anticoagulants and transferred to thrombectomy differ from those of non-hypocoagulated patients.

To compare the time metrics and the functional status of patients with ischemic stroke treated with direct oral anticoagulants and transferred to thrombectomy with non-hypocoagulated patients.

* Corresponding author.

E-mail address: anaisabelsalgueiro@sapo.pt (A.I. Rodrigues).

Methods: This was a retrospective multicenter cohort study involving the eight hospitals involved a regional telestroke network. Clinical, imaging and time measures data were obtained from patients transferred for thrombectomy in the period between 01 January 2016 and 18 March 2021. Reperfusion was assumed for modified Thrombolysis in Cerebral Infarction scores 2b and 3. Functional status was assessed using the modified Rankin scale at 90 days.

Results: Of the 4341 patients evaluated in teleconsultation, 945 patients were transferred for thrombectomy and 15.98% had been previously treated with direct oral anticoagulants. There was no statistically significant difference between groups in the time interval, measured in minutes, between admission to the primary and tertiary hospital (231.59 versus 235.71, $p=0.805$) and, in patients undergoing thrombectomy, between admission to the tertiary hospital and reperfusion (100.45 versus 102.79, $p=0.789$). The reperfusion rate did not differ between groups (86.64% versus 83.57%, $p=0.625$). The functional outcome was not affected by direct oral anticoagulants intake (odds ratio 1.04 [95% confidence interval 0.69-1.55], $p=0.857$).

Conclusion(s): Treatment with direct oral anticoagulants did not have an impact on the performance or the functional outcome of ischemic stroke patients transferred for thrombectomy.

© 2025 Published by Elsevier España, S.L.U. on behalf of Sociedade Portuguesa de Cardiologia. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

PALAVRAS-CHAVE

Acidente vascular cerebral isquémico;
Anticoagulantes orais diretos;
Trombólise;
Trombectomia;
Rede telestroke

Uso de anticoagulantes orais diretos em doentes com acidente vascular cerebral transferidos para trombectomia

Resumo

Introdução e objetivos: As redes regionais para abordagem do acidente vascular cerebral agudo oferecem vantagens, incluindo seleção dos candidatos a trombectomia. Não é claro se o desempenho da rede e o desfecho funcional dos doentes com acidente vascular cerebral isquémico, tratados com anticoagulantes orais diretos e transferidos para trombectomia, é diferente dos não anticoagulados.

Avaliar as métricas de atuação e resultados funcionais dos doentes com acidente vascular cerebral isquémico transferidos para trombectomia tratados com anticoagulantes orais diretos em comparação com os doentes não hipocoagulados.

Métodos: Estudo coorte histórico multicêntrico envolvendo os oito hospitais da Rede Regional. Colhidos dados clínicos, imagiológicos e medidas de atuação dos doentes submetidos a teleconsultas no período entre 01/01/2016 e 18/03/2021 e transferidos para trombectomia. Assumida recanalização para pontuações 2b e 3 no *modified Thrombolysis in Cerebral Infarction*. O estado funcional foi avaliado pela *modified Rankin scale* aos 90 dias.

Resultados: Avaliados 4341 doentes em teleconsulta, 945 foram transferidos para realização de trombectomia; 15,98% dos doentes encontravam-se sob anticoagulantes orais diretos. Não se verificou uma diferença estatisticamente significativa entre grupos no intervalo de tempo, medido em minutos, admissão nos hospitais primário e terciário (231,59 versus 235,71, $p = 0,805$) e, nos doentes submetidos a trombectomia, entre a admissão no hospital terciário e a recanalização (100,45 versus 102,79, $p = 0,789$). A taxa de recanalização não diferiu entre os grupos (86,64% versus 83,57%, $p = 0,625$). O desfecho funcional não foi afetado pela toma de anticoagulantes orais diretos (OR 1,04 [IC95%, 0,69-1,55], $p = 0,857$).

Conclusão: A anticoagulação com anticoagulantes orais diretos não influenciou as métricas de atuação e o desfecho funcional nos doentes transferidos para trombectomia.

© 2025 Publicado por Elsevier España, S.L.U. em nome de Sociedade Portuguesa de Cardiologia. Este é um artigo Open Access sob uma licença CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Stroke is the leading cause of morbidity and functional disability and the second leading cause of mortality in Europe.¹⁻³ As the population ages, an increase in incidence and prevalence is expected in the coming decades. Despite

favorable developments in recent years in primary prevention, secondary prevention and acute phase treatment, stroke remains the leading cause of mortality in Portugal.⁴ In the acute phase, rapid and standardized intervention is essential to increase the likelihood of a good functional outcome. It requires proper recognition of stroke signs and

symptoms in the community, pre-hospital care, transportation to the hospital, prompt medical evaluation and imaging, and initiation of targeted treatment (with transfer to a referral center, if necessary). Early therapeutic intervention is crucial to minimize the probability of irreversible damage and reduce the impact of stroke morbidity and mortality.⁵⁻⁸

Thrombolysis and thrombectomy are first-line recanalization options in eligible patients with acute ischemic stroke.⁶⁻¹¹ Thrombectomy is the only reperfusion treatment available for anticoagulated patients with large vessel occlusion and those in whom intravenous tissue plasminogen activator is contraindicated. Despite their importance in primary and secondary stroke prevention in patients with non-valvular atrial fibrillation (NVAF), the prescription of direct oral anticoagulants (DOACs) has implications for acute-phase therapy. At the time of the study, two groups of DOACs were available in Portugal: factor Xa inhibitors (edoxaban, apixaban, and rivaroxaban) and direct thrombin inhibitors (dabigatran).

The management of patients with ischemic stroke in an emergency context admitted to a primary hospital varies depending on the medication they had taken previously. Thrombolysis is contraindicated in patients who have taken DOACs in the preceding 48 hours and indicated in the rest (excluding other contraindications). Nevertheless, it is unknown whether the functional outcome is different, as the second group initiates reperfusion treatment later at the tertiary hospital.

Regional networks have been developed in recent decades. The central Portugal regional network was created in August 2015 and plays a fundamental role in managing the acute phase of stroke. Regional organizational models for acute stroke management using telemedicine offer several advantages, including upstream selection of thrombectomy candidates.¹²⁻¹⁵ However, it is unclear whether the performance of the telestroke network and the functional outcome of patients with ischemic stroke treated with DOACs and transferred for primary endovascular intervention differ from those of other patients.

Objectives

The objective of this study was, therefore, to evaluate the performance metrics and functional outcome of patients with ischemic stroke transferred for endovascular intervention within a regional network treated with DOACs compared to those not anticoagulated.

Methods

Regional Stroke Fast Track Network (*Via Verde do AVC regional*)

The Regional Stroke Fast Track Network in central mainland Portugal is based on a "drip and ship" model in line with European recommendations and includes seven primary hospitals and one tertiary hospital. Patients are assessed at the nearest hospital capable of performing thrombolysis ("stroke ready hospitals"). When a patient with suspected acute stroke is admitted to a primary hospital, the case is immediately presented to the neurologist responsible for the

stroke unit at the tertiary hospital via a teleconsultation. The results of imaging tests (cranial computed tomography (CT) and cranial and cervical CT angiography, if necessary) are analyzed by a multidisciplinary team using specific software, and if indicated, immediate initiation of thrombolysis and/or emergent transfer for endovascular treatment is proposed. Transportation is provided by the National Institute of Medical Emergency.

Study procedures

A retrospective multicenter observational study was conducted, including the eight hospitals of the Regional Stroke Fast Track Network in the central region of mainland Portugal. Clinical and imaging data were obtained from patients evaluated via teleconsultation with a diagnosis of ischemic stroke due to large vessel occlusion, initially admitted to network primary hospitals and subsequently transferred for thrombectomy, between 01 January 2016 and 18 March 2021. Patients under 18 years old were excluded. Information regarding DOAC prescription and therapeutic adherence was collected from the patients themselves, informants, and from clinical records. Performance metrics and functional outcomes were recorded. Whenever symptom onset was witnessed, the precise time reported by the informant was used. In other cases, the time when the patient was last seen well (LSW) was considered. The intervals between symptom onset/LSW and admission to the primary hospital, admission to primary and tertiary hospitals, and, in patients undergoing thrombectomy, between admission to the tertiary hospital and recanalization were expressed in minutes. Recanalization was assumed for modified Thrombolysis in Cerebral Infarction score (mTICI) scores 2b and 3. Functional outcome was assessed using the modified Rankin scale (mRS) at 90 days. Assessment was conducted in-person whenever possible or by telephone by the responsible physician. Data were collected anonymously, and the research protocol was approved by the ethics committee.

Statistical analysis

Categorical variables were presented as frequencies and percentages and continuous variables were expressed as means and standard deviations. Descriptive and comparative analysis of network performance and functional outcomes between patients treated with DOACs and non-anticoagulated patients were conducted. Statistical analysis included univariate and multivariate analysis adjusted for potential confounding variables. Statistical significance was assumed for p<0.05.

Results

Sample characterization

During the study period (01 January 2016 to 18 March 2021), 4341 patients were evaluated via teleconsultation. Of these, 945 were transferred for thrombectomy, with a mean age of 74.14 ± 12.32 years; 51.53% were women. Demographic characteristics and vascular risk factors are summarized in

Table 1 Demographic characteristics and vascular risk factors of the study population.

	Patients treated with DOACs (n=151)	Non-anticoagulated patients (n=794)	p-Value
Demographic characteristics			
Age (years)	78.44±8.23	73.37±12.79	<0.001
Women, n (%)	89 (58.94)	398 (50.13)	0.047
Vascular risk factors, n (%)			
Hypertension	121 (80.13)	537 (67.63)	0.002
Diabetes	32 (21.19)	160 (20.15)	0.771
Dyslipidemia	82 (54.30)	406 (51.13)	0.475
Non-valvular atrial fibrillation	142 (94.04)	142 (17.88)	<0.001
Smoking	4 (2.65)	81 (10.20)	0.003
Alcoholism	3 (1.99)	40 (5.03)	0.099
Coronary disease	10 (6.62)	46 (5.79)	0.692
Peripheral artery disease	2 (1.32)	13 (1.63)	0.778
Previous stroke	20 (13.25)	50 (6.30)	0.003

Table 2 Clinical characteristics, anticoagulation and acute-phase therapy in the primary hospital of the study population.

	Patients treated with DOACs (n=151)	Non-anticoagulated patients (n=794)	p-Value
Clinical characteristics			
<i>Previous mRankin, n (%)</i>			
0	112 (74.17)	660 (83.12)	
1	20 (13.25)	75 (9.45)	
2	13 (8.61)	32 (4.03)	0.157
3	5 (3.31)	23 (2.90)	
4	1 (0.66)	4 (0.50)	
<i>Anticoagulation, n (%)</i>			
<i>Direct thrombin inhibitor (IIa)</i>	23 (15.23%)	0	-
<i>Factor Xa inhibitors</i>	128 (84.77%)	0	
<i>Therapy in primary hospital</i>			
<i>Fibrinolysis, n (%)</i>	0	547 (68.89)	<0.001

mRankin: modified Rankin scale.

Table 1. There was no statistically significant difference in demographic characteristics and vascular risk factors, except for: age, sex, hypertension, NVAF, smoking, and previous stroke. These variables were included as confounding variables in multivariate analysis. Of the total sample, 151 patients (15.98%) were taking DOACs, of whom 128 patients (84.77%) were medicated with factor Xa inhibitors and 23 patients (15.23%) with direct thrombin inhibitor. Among non-anticoagulated patients, 547 (68.89%) underwent thrombolysis. None of the anticoagulated patients underwent thrombolysis. **Table 2** summarizes the characteristics regarding the degree of prior autonomy of the two groups, type of anticoagulation therapy and treatment in the primary hospital.

Time metrics

There was no statistically significant difference between patients treated with DOACs and non-anticoagulated patients in the time interval, measured in minutes, between

symptom onset/LSW and admission to the primary hospital (158.87 versus 188.77, p=0.124), admission to primary and tertiary hospitals (231.59 versus 235.71, p=0.805), and in patients undergoing thrombectomy, between admission to the tertiary hospital and recanalization (100.45 versus 102.79, p=0.789).

Recanalization rate and functional outcome

The recanalization rate (final mTICI 2b and 3) did not differ significantly between patients treated with DOACs and non-anticoagulated patients (86.64% versus 83.57%, p=0.625); the functional outcome at three months was not affected by DOAC intake (OR 1.04 [95% CI 0.69–1.55], p=0.857). A similar percentage of patients achieved functional independence (43% versus 45%). There was a lower percentage of patients with mRS 0 (7% versus 14%) and a higher percentage with mRS 2 (19% versus 13%) in the DOAC group. Mortality was similar between the groups (19% versus 18%) – **Figure 1**.




Figure 1 Functional results at three months.

Discussion

As expected, some demographic characteristic and vascular risk factors (age, sex, hypertension, NVAF, smoking, and previous stroke) differed significantly among the study groups. In our sample, patients on DOACs were older, more often female, had a higher prevalence of hypertension, NVAF, and previous stroke, and a lower prevalence of smoking. These differences may reflect the epidemiological differences in various vascular risk factors and the main etiologies of stroke, notably the increased prevalence of NVAF (most frequent reason for DOAC introduction) with age and in patients with hypertension or smoking-associated atherothrombotic stroke. The interval between symptom onset/LSW and admission to the primary hospital was greater than 120 minutes in both groups, and no statistically significant difference was identified. Multiple factors contribute to this time interval (identification of stroke signs and symptoms by the patient and the community, activation of pre-hospital emergency services, and distance to the primary hospital). However, the absence of a statistically significant difference may suggest that anticoagulated patients (mostly due to NVAF) and their families are not more aware than the general population of stroke signs and/or symptoms. It is important to note that some of the data are from the period of the SARS-CoV-2 pandemic, which influenced the temporal metrics of the Regional Stroke Fast Track Network in the Central Region of Portugal. In the general population, knowledge about stroke is insufficient. Previous studies have shown that a small percentage of patients contact emergency medical services within the first hour after stroke symptom onset, and less than half recognize stroke as the etiology of their symptoms. These results demonstrate the importance of community awareness programs. The follow-up of patients with NVAF represents an opportunity to alert patients and their families to recognize and act in case of stroke. Medical consultations are an opportunity to promote health education: cardiologists, neurologists, internists, general practitioners,

among others, play a fundamental role in promoting primary and secondary prevention, including lifestyle modification and control of modifiable vascular risk factors. The absence of statistically significant differences in the time intervals between admission to primary and tertiary hospitals and between admission to the tertiary hospital and recanalization may reflect uniformity in the actions of the teams involved at the intra and inter-hospital levels. Regarding the interval between admission to primary and tertiary hospitals, it can be inferred that, in the case of patients meeting the criteria for thrombolysis, the procedure does not delay the transfer process, as it is mostly performed during the activation period of the inter-hospital transfer team. The interval between admission to the tertiary hospital and recanalization did not differ between the groups, as the recanalization rate did. The role of DOACs in the recanalization process needs to be clarified. The analysis of functional outcome at 90 days shows the absence of influence of DOAC medication on the three-month functional outcomes (including mortality) in patients with ischemic stroke and large vessel occlusion transferred for thrombectomy. Patients on DOACs had a similar functional outcome to other patients despite not undergoing intravenous thrombolysis at the primary hospital.

This study has limitations: it is a retrospective study whose data were collected from clinical records that were sometimes incomplete. In addition, the calculation of mRS was evaluated by experienced professionals, but not all with formal certification. The results of this study cannot be extrapolated to other regions due to different protocols of action.

Conclusion

Despite the different approach in acute phase treatment, anticoagulation with DOACs did not influence performance metrics and functional outcome at three months in ischemic stroke patients transferred for thrombectomy.

Learning points

- The intake of direct oral anticoagulants has implications in the acute-phase therapy of ischemic stroke.
- In this study population, thrombolysis did not delay inter-hospital transfer for thrombectomy and did not influence the interval between admission to the tertiary hospital and recanalization.
- In the study population, the recanalization rate and functional outcome did not differ between patients on direct oral anticoagulants and non-anticoagulated patients.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. The atlas of heart disease and stroke. World Health Organization; 2004 [Accessed 16 August 2024]. Available from: <http://www.who.int>
2. Rothwell PM, Coull AJ, Silver LE, et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (oxford vascular study). *Lancet.* 2005;366:1773–83 [PubMed PMID: 16298214].
3. O'Brien JT, Erkinjuntti T, Reisberg B, et al. Vascular cognitive impairment. *Lancet Neurol.* 2003;2:89–98 [PubMed PMID: 12849265].
4. Saúde DGd. Plano Nacional de Saúde 2004-2010. Available from: <http://www.websig.acs.min-saude.pt/websig/acsv2/gui/index.php?par=acs&lang=PRT> [cited 2013].
5. Campbell BCV, Khatri P. Stroke. *Lancet.* 2020;396:129–42.
6. Ackerson T, Adeoye OM, Brown M, et al. AHA/ASA guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke; 2019. p. 344–418.
7. Vieira LGDR, Safanelli J, Araujo T, et al. The cost of stroke in private hospitals in Brazil: a one-year prospective study. *Arq Neuropsiquiatr.* 2019;77:393–403 [PubMed PMID: 31314841].
8. Trigueiro ACQ, Gagliardi RJ. Perfil clínico e funcional de doentes acometidos por acidente vascular cerebral no município de Patos-PB. *Temas Saúde.* 2019;19:86–100.
9. Liu M, Zheng Y, Li G. Safety of recanalization therapy in patients with acute ischemic stroke under anticoagulation: a systematic review and meta-analysis. *J Stroke Cerebrovasc Dis.* 2018;27:2296–305 [Epub 13 July 2018; PMID: 30017747].
10. Frol S, Šabović M, Popović KŠ, et al. Revascularization outcomes following acute ischemic stroke in patients taking direct oral anticoagulants: a single hospital cohort study. *J Thromb Thrombolysis.* 2021;51:194–202 [PMID: 32506363].
11. Zaidat OO, Yoo AJ, Khatri P, et al. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. *Stroke.* 2013;44:2650–63 [Epub 6 August 2013; PMID: 23920012; PMCID: PMC4160883].
12. de Lacerda GM, de Faria IL, Mota LDS, et al. Fibrilação atrial – perspectivas atuais epidemiológicas, fisiopatológicas e terapêuticas. *Braz J Health Rev.* 2024;7:7163–70. Available from: <https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/67597>. [Accessed 16 March 2024].
13. Hubert GJ, Santo G, Vanhooren G, et al. Recommendations on telestroke in Europe. *Eur Stroke J.* 2019;4:101–9 [Epub 26 October 2018; PMID: 31259258; PMCID: PMC6591763].
14. Andrade N, Alves E, Costa A, et al. Knowledge about cardiovascular disease in Portugal. *Rev Port Cardiol.* 2018;37:669–77.
15. Magriço M, Serôdio M, Ramos JN, et al. Are we missing an opportunity? Prehospital delay in patients with acute ischemic stroke and known atrial fibrillation. *Rev Port Cardiol.* 2024;43:321–5.